How are energy investors positioned?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a $643 million market cap biopharmaceutical company, announced Thursday that its 2026 Annual Meeting of Stockholders is scheduled for June 18, 2026. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.35, though its overall financial health score indicates challenges ahead. The company stated that the time and location of the meeting will be provided in its definitive proxy statement, which will be filed with the Securities and Exchange Commission prior to the meeting.
The company noted that the date of the 2026 Annual Meeting differs by more than 30 days from the date of its 2025 Annual Meeting. As a result, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, stockholder proposals intended for inclusion in the proxy materials must be submitted in writing by January 6, 2026. Proposals should be sent to the Corporate Secretary at KalVista’s headquarters in Cambridge, Massachusetts.
In addition, the company’s Amended and Restated Bylaws require that stockholders who wish to present a proposal or nominate a director at the 2026 Annual Meeting, outside of the proxy statement process, must provide notice by August 31, 2025. Stockholders are encouraged to review the Bylaws for further details on advance notice requirements.
KalVista also reminded stockholders who intend to solicit proxies for director nominees, other than the company’s nominees, to comply with the additional requirements of Rule 14a-19 under the Exchange Act.
This information is based on a press release statement included in a filing with the Securities and Exchange Commission.
In other recent news, KalVista Pharmaceuticals has received significant regulatory approvals and analyst attention. The UK Medicines and Healthcare products Regulatory Agency granted marketing authorization for EKTERLY (sebetralstat), marking it as the first oral on-demand treatment for hereditary angioedema (HAE) attacks in the UK. This approval provides EKTERLY with up to 10 years of market exclusivity as it is added to the MHRA’s Orphan Register. Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of sebetralstat in the European Union, with a final decision expected soon. JMP Securities has reiterated its Market Outperform rating for KalVista Pharmaceuticals, emphasizing the potential of the on-demand HAE market. The firm maintains a price target of $27.00 for the company’s stock. Meanwhile, Metagenomi, Inc. announced the appointment of Laurence Reid, PhD, to its Board of Directors, bringing extensive experience in the biotech sector. Reid’s addition is expected to bolster the company’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.